Omalizumab
Title: Omalizumab
CAS Registry Number: 242138-07-4
CAS Name: Anti-(human immunoglobulin E Fc region) immunoglobulin G (human-mouse monoclonal E25 clone pSVIE26 g-chain) disulfide with human-mouse monoclonal E25 clone pSVIE26 k-chain, dimer
Additional Names: olizumab; rhuMAb-E25
Manufacturers' Codes: CGP-51901
Trademarks: Xolair (Novartis)
Literature References: Humanized monoclonal antibody directed against human immunoglobulin E (IgE). Complexes with circulating IgE to prevent the IgE-mediated degranulation of mast cells during an allergic reaction. Prepn: L. G. Presta et al., J. Immunol. 151, 2623 (1993). Pharmacokinetics and effect on circulating IgE levels in allergy patients: J. Corne et al., J. Clin. Invest. 99, 879 (1997). Clinical trial in allergic asthma: H. Milgrom et al., N. Engl. J. Med. 341, 1966 (1999); in allergic rhinitis: T. B. Casale et al., J. Am. Med. Assoc. 286, 2956 (2001). Reviews of clinical efficacy in allergic asthma: S. Holgate et al., Curr. Med. Res. Opin. 17, 233-240 (2001); G. D'Amato, Expert Opin. Biol. Ther. 3, 371-376 (2003).
Therap-Cat: Antiallergic; antiasthmatic.
Keywords: Antiallergic; Antiasthmatic (Nonbronchodilator).

Others monographs:
3-(o-Methoxyphenyl)-2-phenylacrylic Acidβ-Chloropropionic AcidEscinRolitetracycline
Chromous OxalateVitamin TGuaiacol BenzoateDMPA
Indican (Metabolic Indican)Royal JellyScandiumImidocarb
Epibatidinep-Aminohippuric AcidTetranectinCetiedil
©2016 DrugLead US FDA&EMEA